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Abstract: The adrenergic receptors are among the best characterized G protein-coupled receptors (GPCRs) and 
knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of 
the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G protein-
coupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity 
of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding 
to the adrenergic receptor subtypes and we will review more in detail the main proteins found to selectively interact with 
distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes. 
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INTRODUCTION 
 The adrenergic receptors (AR) mediate the functional 
effects of catecholamines, like epinephrine and norepine-
phrine, by coupling to different signaling pathways modula-
ted by G proteins. The adrenergic receptor family includes 
nine different gene products, three β (β1, β2, β3), three α1 
(α1a , α1b and α1d) and three α2 (α2A, α2B and α2C) receptor 
subtypes. 
 The adrenergic receptors, and in particular the β2AR, are 
among the best characterized G protein-coupled receptors 
(GPCRs) and knowledge on this receptor family has 
provided several important paradigms about GPCR function 
and regulation. 
 One of the most recent paradigms initially supported by 
studies on adrenergic receptors is that G protein-coupled 
receptors can act as scaffolds binding a variety of proteins 
and this can promote multiple signaling events which results 
in growing complexity of the receptor-mediated cellular 
effects (reviewed in ref. [1]).  
 In the late 1980s, the first protein found to interact with 
the β2AR, beyond G proteins, was βARK1 (βAR kinase 1) 
[2], discovered as the first member of the G protein-coupled 
receptor kinase family (GRK) [3]. The ability of GRK2 and 
3 to selectively interact with the agonist-bound form of the 
β2AR was a crucial observation to identify their role in 
homologous desensitization.  
 Soon after the discovery of GRKs, it became apparent 
that β2AR desensitization required also the interaction of an 
arrestin protein with the phoshorylated receptor [2, 4]. This 
interaction resulted in both receptor-G protein uncoupling 
and receptor endocytosis into clathrin-coated pits [5].  
 In the last ten years, an important function of βarrestins 
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signaling proteins thus coordinating complex signal trans-
duction events [6]. In particular, it is well established that 
βarrestins are scaffolds for components of the mitogen 
activated protein kinase (MAPK) cascade thus mediating 
MAPK activation induced by various GPCRs. 
 This seminal work encouraged the search for novel 
protein-protein interactions at several GPCRs with the aim of 
identifying previously unappreciated signaling mechanisms 
that might represent new targets of pharmacological inter-
vention. A number of approaches have been followed to 
identify novel proteins interacting with the receptors, 
including yeast two-hybrid screen using cytosolic portions of 
the receptors as bait, pull-down or in vitro overlay assays 
using purified proteins, co-immunoprecipitation of receptor-
protein complexes from recombinant or native cells, FRET 
(fluorescence resonance energy transfer) or BRET (biolu-
minescence resonance energy transfer) technology in cells. 
These studies resulted in the identification of a variety of 
proteins interacting with the adrenergic receptors, several of 
them in a receptor subtype selective pattern. A major chal-
lenge faced by these studies has been to identify the func-
tional implications of these interactions. Some interacting 
proteins have been found to either promote or impair 
receptor-mediated signaling whereas others are involved in 
receptor trafficking or endocytosis.  
 Among the protein-protein interactions found to regulate 
GPCR function, receptor oligomerization has been exten-
sively investigated in recent years [7]. Both homo- and 
hetero-oligomerization have been reported for different 
adrenergic receptor subtypes using different experimental 
approaches. This phenomenon seems to have implications in 
different aspects of receptor function, including its pharma-
cological profile, signaling, trafficking or endocytosis. 
 The canonical interactions of the adrenergic receptors 
with G proteins, GRKs and βarrestins have been extensively 
studied and exhaustively reviewed elsewhere [8, 9]. In this 
review we will briefly summarize the main features of 
βarrestin binding to the adrenergic receptor subtypes and we 
will review, more in detail, a number of proteins found to 
selectively interact with distinct AR subtype. At the end, we 
will review the main findings on oligomerization of the AR 
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subtypes. Considering the large number of studies on pro-
tein-protein interactions at GPCRs, our review might not 
systematically include all published data.  
 The direct interaction of GPCRs with selected partners 
has recently emerged as a new mechanism of receptor 
signaling and regulation. Since these mechanisms might be 
specific for distinct receptors or cell types, the study of these 
interactions has interesting implications in pharmacology 
and drug development.  
βARRESTIN INTERACTION WITH THE AR 
SUBTYPES 
 The well established crucial role played by βarrestin1 and 
2 in coordinating a variety of signaling networks might 
imply that these proteins can form macromolecular comp-
lexes with virtually any GPCR.  
 The interaction of βarrestins with the β2AR has been 
extensively characterized both at functional and molecular 
level using different approaches including in vitro binding of 
purified proteins, co-immunoprecipitation, BRET or FRET, 
βarrestin translocation as well as confocal microscopy to 
assess colocalization of the proteins [6, 8, 9]. The β2AR 
displays a pattern of interaction with βarrestins defined as 
"Class A" characterized by greater affinity for βarrestin 2 
than 1 and a short-lived receptor/βarrestin complex leading 
to rapid receptor recycling after endocytosis. The interaction 
with βarrestins is important in mediating β2AR-induced 
activation of ERK1/2 (see references in [6]). 
 In contrast to the significant amount of data on the β2AR, 
much less is known about the interaction of βarrestins with 
other AR subtypes. The interaction of the β1AR with 
βarrestin is much weaker than that displayed by the β2AR 
subtype and this seems to correlate with the resistance of the 
β1AR to undergo agonist-induced endocytosis [10]. 
However, the β1AR can transactivate the epithelial growth 
factor (EGF) receptor in a βarrestin-dependent mechanism 
and this effect might have implications in cardioprotection 
[11]. This is suggested by a recent study reporting that 
recruitment of βarrestin to the C-tail of the β1AR is required 
for maintaining the β1AR/EGF receptor complex. 
 Also the β3AR does not seem to interact with βarrestins 
as suggested by two lines of evidence. First, the β3AR is 
resistant to agonist-induced endocytosis [12]. Second, the 
ability of the β3AR to activate MAPK is independent from 
βarrestin binding since its activation does not result in 
βarrestin recruitment to the plasma membrane [13]. 
 The interaction of βarrestin with the α2AR was initially 
investigated measuring the effect of overexpressed βarrestin 
on receptor endocytosis [14]. Overxpression of βarrestin 
significantly increased the endocytosis of the α2B and 
α2CAR, but had no effect on the α2AAR suggesting poor 
interaction of this receptor subtype with βarrestin. The lack 
of βarrestin interaction with the α2AAR was confirmed by in 
vitro studies measuring the binding of purified βarrestin to 
peptides derived from the 3i loop of the three α2AR subtypes 
[15].  
 The interaction of the α1a and α1bAR subtypes with 
βarrestin has been investigated by a recent study using dif-
ferent approaches including co-immunoprecipitation, endo-
cytosis and confocal microscopy [16]. Whereas the α1bAR 
displayed robust agonist-induced endocytosis, the α1aAR did 
not. The results from both co-immunoprecipitation experi-
ments and βarrestin translocation assays indicated that the 
agonist-induced interaction of the α1aAR with βarrestin was 
much weaker than that of the α1bAR. The interaction of 
βarrestin with the α1dAR has not been directly explored so 
far. 
 Altogether these findings indicate that the interaction 
pattern of βarrestin with distinct AR subtypes is divergent 
and correlates with differences in the internalization 
properties of the receptors. Overall, despite the large number 
of studies on the β2AR, a lot remains to be explored con-
cerning the implications of βarrestin in adrenergic receptor 
function and regulation. 
PROTEINS INTERACTING AT THE β1AR  
 The first cytoplasmic proteins found to interact select-
ively with the β1AR subtype were endophilins 1/2/3, also 
called SH3p4/p8/p13 [17]. This SH3 domain-containing 
protein family bound the proline-rich third intracellular (i3) 
loop of the β1AR in both pull-down assays and yeast two 
hybrid screens. The primary effect of this interaction was to 
promote agonist-induced internalization of the receptor and 
to modestly decrease its coupling to Gs. Intriguingly, a 
similar proline-rich sequence is found in the i3 loop of the β3 
or α2AAR, but these receptors do not bind endophilins. The 
mechanism through which endophilin might regulate 
receptor coupling and internalization is not known, but it 
could include steric hindrance or allosteric modulation of G 
protein and arrestin binding. 
 A second class of proteins selectively interacting with the 
β1AR are proteins containing the PDZ (PSD-95/Discs-
large/ZO-1 homology) domain which recognizes the extreme 
C-terminus of the target protein. The β1AR possesses a type I 
PDZ binding sequence, E-S-K-V, at the end of its C-tail and 
it has been shown to bind the postsynaptic protein PSD-95 
[18]. This protein is abundant in brain where it co-localizes 
with the β1AR in postsynaptic densities. This interaction was 
found in a yeast two-hybrid screening using the β1AR C-
terminus as bait and it markedly attenuated β1 internaliza-
tion, while having no impact on the receptor desensitization 
or signaling to adenylate cyclase. Association with PSD-95 
could also facilitate the linkage of the β1 to NMDA 
glutamate receptors, known to be regulated by adrenergic 
signaling in the brain, and, more in general, to facilitate 
targeting of the β1AR subtype at synapses. Other studies 
demonstrated that the interaction with PSD-95 is negatively 
regulated by agonist treatment, through phosphorylation of 
the receptor by GRK5, thus allowing receptor internalization 
[19].  
 A second PDZ domain containing protein interacting 
with the β1AR is membrane-associated guanylate kinase 
inverted-2 (MAGI-2), a multidomain scaffold protein, also 
known as S-SCAM (synaptic scaffolding molecule). The 
first PDZ domain of MAGI-2 binds with high affinity to the 
β1AR C-tail, as demonstrated by overlay and pull-down 
techniques [20]. The β1AR/MAGI-2 interaction occurred 
constitutively in cells, but it was further enhanced by isopro-
terenol treatment. It favored agonist-induced internalization 
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of the receptor, an effect opposite to the one observed for 
PSD-95, another PDZ-domain protein [18]. MAGI-2 also 
promoted β1AR association to βcatenin, a known MAGI-2 
partner.  
 A third PDZ domain containing protein binding the β1AR 
is GIPC (Gα-interacting protein-interacting protein, C ter-
minus) [21]. This interaction decreased ERK1/2 activity 
stimulated by the β1AR, through a Gi-dependent process, 
with no observable effects on the Gs-mediated cAMP accu-
mulation or on receptor internalization. One last example of 
a PDZ domain-mediated interaction with the β1AR is CAL 
(Cystic Fibrosis Transmembrane Conductance Regulator-
Associated Ligand), found by pull-down techniques to 
interact with the ESKV sequence of the β1AR [22]. Over-
expression of CAL, a protein localized in the Golgi appara-
tus, reduced surface expression of the receptor, a process 
competitively reversed by PSD-95. 
 GPCRs can indirectly activate Ras through the Gβγ 
subunits of the G protein that can recruit c-Src, Grb-Sos and 
PI3 kinase. The β1AR was the first GPCR for which a direct 
interaction with a Ras-GEF (GTP exchange factor), 
CNrasGEF, had been described [23]. CNrasGEF bound the 
ESKV sequence of the β1AR through its PDZ domain and 
mediated isoproterenol-induced Ras activation.  
 The importance of the PDZ binding sequence in the C-
tail of the β1AR was highlighted by findings obtained 
expressing the receptor in mouse cardiac myocytes [24]. In 
these cells, stimulation of the β1AR increases the contraction 
rate, whereas the β2AR has a biphasic effect with an initial 
increase followed by a decrease mediated by receptor 
coupling to Gi. In addition, whereas the β2AR undergoes 
endocytosis, the β1AR does not. Interestingly, the mutation 
of the PDZ binding sequence of the β1AR enabled both 
receptor internalization and coupling to Gi thus providing 
evidence that differences in the interaction with PDZ 
containing proteins might dictate the distinct physiological 
effects induced by the two βAR subtypes.  
 Each of the four PDZ domain containing proteins above 
described, although binding to the same sequence of the 
β1AR, exerted different effects both on receptor trafficking 
and signaling. It is noteworthy that these four proteins do not 
share the same tissue distribution, PSD-95 and MAGI-2 
being almost exclusively found in the brain, whereas GIPC 
and CNasGEF being predominantly expressed in the heart. A 
recent proteomic screen aimed at providing an exhaustive 
view of PDZ-mediated interactions at the β1AR, confirmed 
the association with PSD-95, MAGI-2, GIPC and CAL, and 
identified two novel ones, SAP97 and MAGI-3 [25]. MAGI-
3 co-expression profoundly impaired β1AR-mediated 
ERK1/2 activation.  
 To assess the GPCR selectivity of these interacting 
proteins a recent study used a library of 59 GPCR C-tails, 
among which those of the β1 and β2AR, in a pull-down assay 
[26]. This approach identified the lysosomal targeting 
protein GASP1 (G protein-coupled receptor-Associated 
Protein) as a potential interacting partner of the β1AR, but 
this finding was not explored further. GASP1 had been 
previously identified in a yeast two-hybrid screen as a 
protein interacting with the C-tail of the δ opioid receptor 
and shown to interfere with the post-endocytic sorting of the 
receptor. It was later discovered that GASP1 is member of a 
family of ten proteins displaying some sequence similarities 
whose functional implications are still largely unknown 
(reviewed in [27]). Whereas GASP1 can interact with several 
GPCRs other proteins of this family have been shown to 
modulate transcription. Considering these two important 
features, the GASP proteins might represent a promising area 
of investigation in the GPCR field.  
 Another protein recently shown to interact with the β1AR 
and influence it’s trafficking is golgin-160 which is a ubiqui-
tously expressed Golgi membrane protein [28]. Golgin-160, 
whose function in Golgi structure is unknown, can interact 
with the third intracellular loop of the β1AR and its depletion 
in cells leads to a significantly reduced cell surface expres-
sion of the receptor.  
 An interesting interaction was recently found between the 
β1AR and the adaptor protein 14-3-3epsilon both in recom-
binant cells and heart [29]. The receptor/14-3-3 complex can 
compete with the interaction occurring between 14-3-
3epsilon and the voltage-gated potassium channel, Kv11.1, 
and this might represent a mechanism involved in adrenergic 
regulation of cardiac repolarization. Whereas the wild type 
β1AR inhibits potassium current, a receptor mutant lacking 
its interaction with 14-3-3 can activate it. This is a fasci-
nating finding highlighting the role of multiple protein inter-
actions in fine tuning of the physiological effects mediated 
by the adrenergic receptors on cardiac rhythms.  
 Another finding highlighting the potential functional 
impact of different signaling complexes in heart cells 
concerns the interaction of the β1 and β2AR subtypes with 
phosphodiesterases (PDE) [30]. Whereas the β2AR forms a 
complex with βarrestin and the PDE4D5 isoform, the β1AR 
can directly interact with the PDE4D8 isoform and the 
agonist can dissociate this complex. Both the receptor and 
PDE4 are regulated in a complex manner by the cAMP/PKA 
cascade and binding of PDE4D to the β1AR might allow for 
the control of cAMP levels in proximity of the receptor. 
PROTEINS INTERACTING AT THE β2AR  
 PDZ domain-mediated interactions are also known to 
occur at the C-tail of the β2AR, which includes the type I 
PDZ-binding C-terminal sequence D-S-L-L. The first protein 
found to interact specifically with this sequence of the β2AR, 
but not with β1AR, was NHERF1 (Na+/H+ Exchanger 
Regulatory Factor 1), also named EBP50 (ERM- Binding 
Protein 50) [31]. This protein contains two PDZ domains and 
regulates the activity of the Na+/H+ exchanger type 3 
(NHE3). In addition, NHERF factors represent a well 
established link between ERM (Ezrin-Radixin-Moesin) 
proteins and specific polytopic membrane proteins [32]. The 
β2AR/NHERF interaction might play a role in the receptor-
mediated regulation of cellular pH. Typically, an increase of 
intracellular cAMP levels inhibits NHE3 activity (via PKA-
mediated phosphorylation of NHERF), but the stimulation of 
the β2AR potentiates it. This is probably due to the fact that 
binding of the β2AR to NHERF relieves the NHERF-
mediated inhibition of NHE3.  
 NHERF can also be a link between the β2AR and other 
proteins which interact with NHERF, such as the platelet-
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derived growth factor (PDGF) receptor [33] and cystic 
fibrosis transmembrane conductance regulator (CFTR) [34]. 
Whereas PDGF receptor-mediated signaling is potentiated 
by its interaction with NHERF, the formation of the β2AR/ 
NHERF complex might regulate PDGF receptor function. A 
macromolecular complex composed of the β2AR, CFTR and 
NHERF was shown to form in human airway epithelia and 
this complex might represent an important mechanism 
underlying the β2AR-stimulated increase of CFTR activity. 
 In addition to mediating these functional effects of the 
β2AR, the interaction with NHERF seems to play a direct 
role in receptor trafficking. The β2AR is a member of class A 
GPCRs, being characterized by rapid agonist-induced 
endocytosis and recycling back to the plasma membrane. It 
was demonstrated that disruption of either NHERF binding 
to the β2AR or NHERF binding to the actin cytoskeleton 
(mediated by NHERF/ERM interaction) caused missorting 
of endocytosed β2AR to the degradation pathway and 
prevented its recycling [35]. Actin depolymerization had a 
similar effect, implying that anchoring of the receptor to the 
actin cytoskeleton through NHERF and ERM proteins 
ensures its proper trafficking following endocytosis. A 
similar role for NHERF in directing the recycling of several 
other GPCRs was subsequently documented [32].  
 Another protein that associates with the distal part of the 
β2AR C-tail is NSF (N-ethylmaleimide-Sensitive Factor) 
[36]. Despite lacking PDZ domains, NSF also recognizes the 
extreme C-terminal sequence D-S-L-L and its association 
with the receptor is increased upon agonist treatment. NSF 
binding to the β2AR was shown to be required for both 
receptor internalization and recycling, but it is unclear 
whether a competition between NSF and NHERF binding to 
the receptor takes place and how this process is regulated. 
 The role of the PDZ binding sequence in the β2AR was 
validated in cardiac myocytes by the same group which 
investigated the β1AR-mediated effects on contraction rate 
[37]. Deletion of the PDZ binding motif in the β2AR 
abolished its coupling to Gi resulting in higher contraction 
rate, in contrast to the effect observed for the β1AR, where a 
similar mutation promoted Gi coupling and decreased 
contraction [24]. In agreement with previous findings, the 
mutated β2AR lacking interaction with NHERF was unable 
to recycle back to the plasma membrane. The experimental 
design did not allow to discriminate between NSF- and 
NHERF1-mediated effects.  
 Stimulation of the β2AR raises intracellular cAMP levels 
leading to activation of protein kinase-A (PKA). The 
functional connection between the β2AR and PKA prompted 
the investigation on potential interactions between this 
receptor and PKA-anchoring proteins, or AKAPs. The first 
AKAP found to bind the β2AR was AKAP250, also known 
as gravin. Association of gravin to the receptor was 
increased upon agonist treatment [38] and involved the C-
terminal portion of the receptor [39]. Suppression of gravin 
expression using an antisense strategy disrupted receptor 
resensitization and impaired its association to GRK2, 
βarrestin and clathrin, suggesting that gravin might serve as 
a scaffold bringing together kinases, phosphatases and 
proteins of the endocytic machinery.  
 Another AKAP, AKAP79, directly and constitutively 
interacts with the β2AR and promotes its phosphorylation by 
PKA, which is obligatory for MAPK activation by the 
receptor [40]. The anchored PKA was further shown to 
phosphorylate GRK2 enabling its translocation to the 
membrane and subsequent phosphorylation of the β2AR 
[41]. Thus, AKAP79 is involved in the process of β2AR 
desensitization and internalization through the clathrin-
dependent pathway. The molecular determinants of the 
receptor interaction with AKAPs were unfortunately not 
finely mapped and the question of the specificity of this 
interaction among adrenergic receptor subtypes has not been 
addressed yet. 
 An interaction of the β2AR with the adaptor protein Grb2 
has also been reported [42]. This interaction was not 
identified through unbiased screening, but specifically tested 
based on the observation that insulin abolishes catechol-
amine response by stimulating tyrosine phosphorylation of 
the β2AR. This phosphorylation creates an SH2 site on the 
β2AR which induces Grb2 binding to the receptor at 
Tyr250/254 thus leading to receptor-G protein uncoupling. 
Grb2 binding to the receptor was increased upon cell treat-
ment with insulin and promoted also receptor internalization 
[43]. 
 Interesting interactions have been found between the 
β2AR and ion channels involved in the regulation of mem-
brane excitability. The β2AR was found to directly interact 
with the voltage-gated calcium channel Cav1.2 in hippo-
campal neurons [44]. A complex containing the β2AR, the 
Cav1.2, G protein, an adenylate cyclase, PKA and the PP2A 
phosphatase might represent a mechanism ensuring a 
specific and highly localized signaling process.  
 It is well known that β2AR and PKA activation can 
increase BKCa activity in neurons, smooth muscle cells and 
other excitable cells. Recent findings indicate that the β2AR 
can interact with calcium sensitive K+ channels (BKCa) in a 
complex containing the receptor, BKCa and AKAP79 [45]. 
Thus, the β2AR might interact with both the Cav1.2 calcium 
channel and the BKCa calcium sensitive K+ channel, and 
these interactions might enable a highly localized control of 
membrane excitability. 
 A recent study reports a fascinating finding concerning 
the interaction between the β2AR and two proteins, the von 
Hippel-Lindau tumor suppressor protein (pVHL)-E3 ligase 
complex and the dioxygenase EGLN3 [46]. It is known that 
in response to hypoxia there is a decreased expression of 
β1AR in heart attributed to high levels of catecholamines 
whereas the β2AR abundance increases suggesting a direct 
regulation of this receptor by oxygen. The metallo-sensory 
enzyme dioxygenase EGLN3 transduces O2-responsive 
signals through modifications of target proteins. Thus, the 
interaction of EGLN3 with the β2AR results in hydroxylation 
of Pro382 and Pro395 of the receptor. After hydroxylation of 
the β2AR, pVHL-E3 ligase is recruited triggering ubiquitiny-
lation of the β2AR and its degradation. This finding 
highlights the broadness and complexity of protein-protein 
interactions that can be explored to understand receptor 
function and regulation. 
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PROTEINS INTERACTING AT THE β3AR 
 The β3AR subtype was cloned several years after the 
other βAR subtypes and its distribution seems to be res-
tricted to adipose tissue, skeletal and smooth muscles. For 
these reasons little is known to date about the specific 
interactions of this AR subtype. One cytoplasmic partner has 
been identified, namely the tyrosine kinase Src, that can bind 
through its SH3 domain to the polyproline region in the third 
intracellular loop and the C-tail of the receptor [13]. The 
direct binding of Src of the β3AR seems required for ERK1/2 
activation by the receptor. Previous reports from the same 
group had demonstrated an involvement of Src in MAPK 
activation by the β2AR, but this effect was mediated by the 
interaction of Src with βarrestin. As mentioned above, direct 
Src binding to the β3AR occurred through its SH2 domain on 
the phosphotyrosine Tyr350. The paucity of data regarding 
β3AR interactions leaves open an entire field of investigation 
in the signaling of this receptor. 
PROTEINS INTERACTING AT THE α1AAR 
 Few interactions have been shown to occur selectively at 
the α1aAR subtype. Yet, this receptor contains a PDZ bind-
ing sequence G-E-E-V at its C-terminus that can be expected 
to give rise to PDZ-domain mediated interactions. An early 
report, at the issue of a yeast two-hybrid screen, identified 
the type III PDZ domain of nNOS (neuronal nitric oxide 
synthase) as a potential α1aAR interacting protein [47]. 
However, co-immunoprecipitation studies, while confirming 
this interaction, failed to highlight selectivity for the α1aAR 
subtype since all three α1AR subtypes could be co-
immunoprecipitated with nNOS and this even when they 
were lacking their C-terminus. This interaction appeared to 
be without apparent physiological implications in spite of the 
known role of NO in the regulation of blood pressure and of 
nNOS as local metabolic inhibitor of α1AR-mediated 
vasoconstriction.  
 Another study reported that mammalian tolloid (mTLD) 
could interact with the α1aAR [48]. The CUB5 domain of 
mTLD, a zinc-finger matrix metalloprotease of the astacin 
family, interacted with α1aAR C-tail in a yeast two hybrid 
screen. The interaction was specific for the α1aAR and the 
binding region on the receptor could be narrowed down to a 
sequence of 37 aminoacids. Overexpression of mTLD 
reduced the number of cell surface receptors without affect-
ing total receptor level or affinity when transiently expressed 
in HEK293 cells. mTLD also appeared to facilitate calcium 
signalling evoked by phenylephrine. No mechanism was 
proposed to account for the observed phenomena. 
 Interesting prospects were opened by the report of the 
direct interaction between RGS2 (Regulator of G protein 
Signaling 2) and the third intracellular loop of the α1aAR 
[49]. RGS proteins are well characterized inhibitors of 
heterotrimeric G protein function, acting as GAPs (GTPase 
activating proteins) to increase the rate of GTP hydrolysis at 
Gα subunits and thus terminate signaling. More than 30 RGS 
proteins have been identified so far, but many RGS proteins 
can non-selectively bind to and inhibit Gαi/o and Gαq11 in 
reconstituted systems, suggesting that other factors may 
regulate their specificity for a particular signaling pathway. 
RGS2 was found to interact with the α1aAR third intra-
cellular loop confirming what previously shown for other 
Gq-coupled receptors, namely the cholinergic muscarinic 
M1, M3 and M5 receptors [50] and it inhibited agonist-
induced inositol phosphate responses without affecting 
ligand binding. 
PROTEINS INTERACTING AT THE α1BAR  
 Two main interacting partners were pulled out of a yeast 
two-hybrid screen for the α1bAR: the µ2 (or AP50) subunit 
of the clathrin adaptor complex AP2 [51] and ezrin, a mem-
ber of the ERM protein family [52]. The AP2 complex is 
part of the endocytic machinery mediating clathrin-depend-
ent endocytosis of membrane proteins and it is recruited to 
agonist-activated GPCRs through the intermission of 
βarrestins. Interactions of the AP50 subunit are dependent 
upon a YxxF motif present in the cargo protein. However, in 
the case of the α1bAR, binding of AP50 relied on a basic 
stretch of eight arginines in the proximal C-tail of the recap-
tor. Direct association of the α1bAR to AP50 contributed to 
the agonist-induced internalization of the receptor as 
demonstrated by the fact that a receptor mutant lacking the 
AP50 binding motif was delayed in internalization. The 
presence of the eight arginine motif in the C-tail of a GPCR 
is not common, which rules out the hypothesis that direct 
AP50 interaction is a common mechanism for clathrin-
mediated endocytosis. Interestingly, this feature is shared by 
the α1dAR, which contains a stretch of seven positive 
charges in its C-tail, but no studies were undertaken using 
this receptor subytpe. 
 In addition to AP50, the same yeast two-hybrid screen 
identified ezrin as a potentially direct binding partner of the 
α1bAR [52]. Ezrin belongs to the ERM family of proteins, 
primarily described as linkers between membrane proteins 
and cortical actin. Ezrin was also shown to be involved in the 
remodelling of the actin cytoskeleton, in the modulation of 
Rho signaling (by binding to Rho GTP dissociation inhibitor 
(GDI) and through direct association to several Rho 
GTP/GDP exchange factors (GEFs) as well as in anchoring 
of PKA. Ezrin interactions with polytopic membrane 
proteins generally occur through the adaptor proteins EBP50 
(NHERF1) and E3KARP (NHERF2), but direct contacts 
were also described between ezrin and proteins such as the 
Na+/H+ exchanger type 1 (NHE1) and podocalyxin. So far, 
a role for the ERM proteins in GPCR trafficking was 
inferred from the finding that NHERF1 binding to some 
GPCRs promoted their recycling, depending on its binding 
to ERM proteins. The α1bAR is the first GPCR for which a 
direct interaction with ezrin has been found. Disruption of 
this interaction by overexpression of a dominant negative 
mutant of ezrin inhibited receptor recycling after internaliza-
tion, as did actin depolymerization. Thus, the involvement of 
ERM proteins in GPCR recycling, through either a direct or 
indirect interaction with the receptor, might represent a 
general paradigm for the regulation of GPCR trafficking.  
 Intriguingly, ezrin and AP50 shared the same binding site 
on the α1bAR C-tail, consisting in the eight arginines stretch 
positioned after the putative palmitoylation site. In pulldown 
experiments the binding domain of ezrin and that of AP50 
competes with each other for the same binding site of the 
receptor C-tail (unpublished data). How these events are 
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regulated within the cell is a matter that awaits further 
inquiry. 
 Another protein, the receptor for globular "Heads" of c1q 
(gC1qR), was reported to interact with the same arginine-
rich sequence in the α1b and the α1dAR [53]. gC1qR is a 
glycoprotein mainly displaying intracellular localization, but 
also present on the surface of macrophages and T cells 
through anchoring to β-integrin, where it is part of a com-
plement receptor. No functional relevance was demonstrated 
for its interaction with the α1b or α1dAR. 
PROTEINS INTERACTING AT THE α1DAR 
 The α1dAR was for a long time a “poor relative” to the 
other α1AR subtypes, the α1a and α1b because poorly exp-
ressed at the cell surface in heterologous systems, probably 
because of its long N-terminus. This peculiarity hampered 
the investigation of its potential interactions with other 
proteins. Apart from the above mentioned interaction with 
gC1qR, whose functional implications are unknown [53], 
another interacting partner of the α1dAR was α-syntrophin 
[54]. α-syntrophin, a protein containing one PDZ domain 
and two PH (pleckstrin homology) domains, specifically 
recognized the C-tail of the α1dAR, but not that of the α1a or 
α1b, in the yeast two-hybrid assay. The PDZ domains of 
syntrophin isoforms α, β1 and β2, but not γ1 or γ2, could 
interact with the α1dAR C-tail. The α1dAR possesses the C-
terminal sequence E-T-D-I, whose mutation impaired 
syntrophin binding to the receptor and markedly decreased 
norepinephrine-induced inositol phosphate accumulation. 
This mutation also dramatically decreased receptor expres-
sion levels. Interestingly, syntrophins seemed to interact 
equally well with intracellular or surface-expressed α1dAR 
receptors. Taken altogether these results suggested that 
syntrophins act to maintain the stability of the α1dAR 
through a PDZ-mediated interaction. 
PROTEINS INTERACTING AT THE α2AR SUB-
TYPES 
 The three α2AR receptor subtypes (α2A α2B and α2C) 
are coupled to the Gi/o family of heterotrimeric G proteins, 
and hence to the inhibition of adenylyl cyclase and voltage 
sensitive calcium channels, and to the activation of potas-
sium channels. They are differently expressed in various 
tissues including the basolateral membrane of polarized renal 
epithelial cells where differences in the targeting and 
trafficking of the three subtypes have been found. The proper 
basolateral retention of the α2AR receptor subtypes is 
dependent upon the integrity of their third intracellular loop, 
a finding which prompted the search for partners interacting 
with this region of the receptors. A gel overlay strategy using 
in vitro translated i3 loops of the α2AR receptors highlighted 
the interaction of the zeta isoform of 14-3-3-proteins [55]. 
14-3-3 proteins are ubiquitous and involved in the regulation 
of a number of signaling pathways, among which the Ras/ 
MAPK cascade. 14-3-3 interacted preferentially with the α2A 
and α2B than with the α2C. A detailed study of the sequence 
requirements for this interaction at the α2AAR did not 
identify a single linear motif suggesting that a three 
dimensional structure in the i3 loop is needed for 14-3-3 
binding [56]. 
 An important binding partner of all three α2AR subtypes 
is spinophilin [57, 58]. This interaction was specifically 
tested with the rationale that spinophilin is enriched beneath 
the basolateral membrane of MDCK cells. Spinophilin 
binding to α2AAR was enhanced by agonist treatment and the 
region responsible for binding was loosely mapped to the N- 
and C-terminal ends of the i3 loop [56]. Interaction with 
spinophilin contributed to the cell surface stabilization of the 
α2BAR subtype, a receptor that displays the unique property 
of being first randomly delivered to both apical and 
basolateral side of the cell, with a much faster apical versus 
basolateral turnover which ends up in its accumulation on the 
basolateral side. Apical delivery of a spinophilin subdomain 
extended the half-life of the α2BAR in this region; further-
more, agonist-stimulated internalization of the receptor was 
accelerated in fibroblats derived from spinophilin knock-out 
mice [59]. Presumably, similar effects could occur at the 
other two α2AR subtypes. An explanation of this effect came 
from the finding that spinophilin blocks GRK2 association to 
the α2BARs thus inhibiting receptor endocytosis [60].  
 Spinophilin was also found to interact with other GPCRs, 
including the α1bAR, as well as with the N-terminal domain 
of RGS proteins (RGS1, 2, 4 and 16) which participates in 
GPCR recognition [60, 61]. Thus spinophilin might 
represent an interesting functional bridge between RGS and 
α1AR subtypes that don't bind RGS, like the α1bAR. In fact, 
it has been found that spinophilin increases the RGS2-
induced inhibition of the α1bAR calcium response. In support 
of this finding, a constitutively active α1bAR mutant did not 
bind spinophilin and was resistant to inhibition by RGS2. 
Similar resistance to RGS2 inhibition was found to occur in 
spinophilin knock-out cells. These data offer a glimpse into a 
potentially more general regulatory mechanisms of GPCR 
function by spinophilin. 
 The most recent protein found to interact with α2ARs is 
ubiquitin carboxyl-terminal hydrolase-L1 (Uch-L1), a 
protein associated with Parkinson disease [62]. Uch-L1 binds 
preferentially to the α2AAR subtype and its overexpression 
inhibits the receptor-induced activation of MAPK. This 
interaction might have implications in the neuroprotective 
effect of α2ARs which needs to be further investigated. 
OLIGOMERIZATION OF THE ADRENERGIC 
RECEPTORS 
 Findings in the last decade challenged the widely held 
view of GPCRs functioning as monomeric units [7]. Early 
biochemical studies showing higher molecular weight recap-
tor bands migrating in SDS-PAGE gels, stabilized by cross-
linking, suggested that adrenergic receptors might form 
oligomers. Afterwards, co-immunoprecipitation of differen-
tially tagged GPCRs or functional complementation of pairs 
of co-expressed inactive receptor mutants provided stronger 
evidence in favor of GPCR oligomers. The widespread use 
of biophysical techniques such as FRET or BRET between 
GPCRs carrying the appropriate pair of fluorescent/ 
bioluminescent labels suggested oligomerization of a variety 
of GPCRs. Each technique employed has its own shortcom-
ings: whereas co-immunoprecipitation cannot rule out indi-
rect interactions, energy transfer techniques can only certify 
that the two partners are in close proximity, not necessarily 
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in immediate contact. Therefore, whether receptor oligomeri-
zation involves direct interactions among receptor monomers 
versus their increased proximity in micro-domains of the cell 
membrane cannot be unequivocally demonstrated. Despite 
the fact that the precise molecular events are not fully 
understood, the term of GPCR oligomerization is largely 
accepted to indicate the existence within the cell membrane 
of macromolecular complexes formed by two or more 
receptor monomers. It is important to highlight that most 
studies have been performed in recombinant cells overexp-
ressing the receptors with very few examples of oligomeriza-
tion occurring in physiological systems. 
Homo-Oligomerization 
 Within the adrenergic receptor family, the β2AR was the 
first member for which homo-oligomerization was described, 
using co-immunoprecipitation of epitope-tagged receptors 
[63]. BRET technology was then adapted for the purpose of 
showing the existence of receptor oligomers at the cell sur-
face and of quantitatively assessing the extent of oligomeri-
zation [63, 64]. Homo-oligomerization was therefore 
demonstrated for the β2AR [63, 64], β1AR [65], α1a and α1b 
[66, 67], α1d [67], α2a and α2c [68], and for the α2b [69] AR 
subtypes. 
 Whereas the stoichiometry of these complexes is hard to 
assess with either biochemical or biophysical methods used 
so far, the structural architecture of receptor oligomers has 
been addressed by some studies using computational, phar-
macological and biochemical approaches. Two types of 
receptor-receptor interaction have been proposed, involving 
either lateral contact or domain swapping. A model was 
proposed for a β2AR dimer where the two receptor mono-
mers swapped helices V and VI [70]. Other studies pointed 
at helices I and VII [66] or I/II and III/IV [71] as the 
probable interface for receptor-receptor contact in the case of 
the α1b AR. Neither the C-terminal tail of the α1bAR nor its 
glycosylation state or the presence or absence of a glycol-
phorin dimerization motif GxxxG in the transmembrane 
domains affected its oligomerization [66]. This was in 
contrast with the previous report of Hébert et al., showing 
that helix VI containing the GxxxGxxxG motif was 
responsible for oligomerization of the β2AR [63]. 
 The functional implications of AR homo-ligomerization 
have been explored by several studies. Preventing receptor 
association has been technically difficult with few excep-
tions. In the case of the β2AR, a peptide derived from helix 
VI was shown to disrupt dimerization and its use was 
demonstrated to impair isoproterenol-stimulated cAMP 
production by the β2 AR [63] implying that β2 oligomers 
would be the functional form of the receptor. 
 Among the functional implications of AR homo-
oligomers, different studies investigated their localization 
within the cell. BRET studies suggested that β2AR oligomers 
are present at the plasma membrane [64]. Biotinylation with 
a membrane-impermeable showed expression of α1a, α1b and 
α1d homodimers at the cell surface [67]. Moreover, homo-
oligomerization of the β2AR seems to be a prerequisite for 
its plasma membrane targeting [72]. In fact, the peptide 
derived from helix VI of the β2AR, which blocks receptor 
oligomerization, prevented normal targeting of the receptor 
to the plasma membrane. These results imply that receptor 
oligomers form as early as the stage of their synthesis in the 
endoplsmic reticulum and that oligomerization influences 
their maturation and trafficking ability from then onwards. 
Indeed, co-expression with a recycling-defective mutant 
diverted wild type β2AR from normal recycling to the 
plasma membrane to the proteolytic degradative pathway 
[73]. Similar data were obtained for the α2BAR subtype; 
when co-expressed with a mutant deficient in cell surface 
targeting, the wild type α2BAR remained trapped in the 
endoplsmic reticulum [69]. 
 A matter of debate has been the regulation of the 
oligomeric status of GPCRs by ligands. One among the first 
reports indicated that agonist binding could increase the 
amount of β2AR dimers [63], corroborated by BRET data 
[64]. In contrast, agonist treatment had no apparent effect on 
the oligomerization of α1AR subtypes [66, 67]. Furthermore, 
constitutively active or non-functional α1bAR mutants 
displayed the same propensity to oligomerize as the wild 
type receptor [66], indicating that the activation state of the 
receptor is irrelevant for this process. 
Hetero-Oligomerization 
 Different AR subtypes are often co-expressed in the same 
cells and cross-talk among them can occur. Various studies 
addressed the hypothesis that hetero-oligomerization could 
account for cross-talk effects. A number of interactions 
between different AR subtypes or between ARs and more 
distantly related GPCRs have been reported (Table 2).  
 The adrenergic receptor subtypes seem to display 
selectivity of interaction and hetero-oligomers do not form 
for any two receptor combination. Within the AR family, the 
following main hetero-oligomers have been found: β1/β2 
[74], β2/β3 [75], α1b/α1a and α1b/α1d, (but not α1a/α1d) [66, 67, 
76], α1b/β2 [66], α1d/β2 [77], α2A/α2C [68], α2A/β1 [78] and 
α2C/β2 [79].  
 In addition, the following main combinations have been 
described between AR subtypes and other GPCRs: β2AR/ 
olfactory receptor [80], β2AR/δ opioid and β2AR/κ opioid 
[81], βAR/AT1 angiotensin II [82], β2AR/5-HT4 serotonin 
[83], β2AR/EP1 prostaglandin [84], β2AR/CB1 cannabinoid 
[85], α2A/µ opioid [86] and α2A/δ opioid [87]. Very recently 
a macromolecular complex including the β2AR, Gs, PKA, 
adenylate cyclase and the AMPA glutamate receptor, 
mGluR1, has been described [88]. 
 Hetero-oligomerization was found to have various 
functional effects upon the behavior of individual receptors, 
ranging from regulated targeting to modified pharmacolo-
gical, signaling or trafficking profile in recombinant systems. 
Co-expression of the α1dAR with the α1bAR [76] or the 
β2AR [77] was able to rescue surface expression of the 
α1dAR, the majority of which is intracellular when expressed 
alone in various cell lines. A similar phenomenon was 
already observed for the GABA-B receptor and for the 
calcitonin/adrenomedullin receptor, both receptors needing 
hetero-dimerization in order to be properly targeted to the 
plasma membrane. Interestingly, the interaction with the 
α1bAR modified the pharmacological profile of the α1dAR 
which looses its affinity for its selective ligand BMY7378 
when it is co-expressed with the α1bAR. The α1b/α1d dimer 
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behaves as a single functional entity with increased response 
to norepinephrine relative to either monomer alone. The 
α1dAR receptor was long supposed to be little expressed in 
the heart, as its selective ligand BMY7378 could detect only 
minimal levels of the receptor. However, these findings 
should be considered in a new light, given that the α1b and 
α1dAR subtypes co-exist in this tissue and the pharma-
cological profile of the α1dAR might be different than 
expected because of oligomerization.  
 Hetero-dimerization of the β2AR with the α2CAR, which 
is normally poorly expressed in recombinant cells, increased 
the expression at the cell surface and ERK1/2 signaling of 
the α2CAR [79]. Coexpression of the α2CAR with more than 
twenty-five GPCRs revealed that only the β2AR induced this 
effect. Coexpression of the β2AR with the olfactory receptor 
(M71) also promoted the cell surface localization of this 
receptor which is often co-expressed with the β2AR in 
olfactory neurons [80]. Again, only the β2AR among the AR 
subtypes had this effect.  
 Beyond its effect on receptor targeting to the cell surface, 
hetero-oligomerization seems to have an impact on various 
aspects of receptor trafficking and signaling. For example, 
several studies have shown that receptor monomers can 
mutually influence their endocytosis pattern. Whereas the 
α1bAR undergoes agonist-induced internalization, the α1aAR 
does not. However, when the two AR subtypes were co-
expressed forming heterodimers, the endocytosis of each 
monomer could be triggered by stimulation of the other [66]. 
Colocalization of the two monomers could be seen in 
endocytic vesicles suggesting that the α1a/α1b dimers 
remained stable throughout the endocytosis process.  
 Strikingly, in β1/β2 heterodimers, the internalization of 
the β2AR within the complex was inhibited. Furthermore, 
β2AR-induced ERK activation was equally blocked by co-
expression of β1AR [78]. Similar results were also found for 
the β2/β3 heterodimer [79] in which β2AR internalization was 
impaired. The β3AR is resistant to agonist-promoted 
endocytosis and, like the β1AR, acted as a dominant negative 
on β2AR internalization. 
 In α2A/β1 heterodimers, stimulation of the α2AAR trig-
gered the internalization of the β1AR [78]. In addition, the 
β1AR within the heterodimer displayed altered pharmaco-
logy. In α2A/α2C heterodimers, the GRK-dependent phospho-
rylation and βarrestin recruitment at the α2AAR, were 
inhibited [68]. 
 Functional cross-talk was also described between the 
β2AR and the opioid receptors (OR) that are coupled to 
stimulatory and inhibitory G proteins, respectively. Whereas 
in the β2/δ opioid dimer the β2AR and δOR could facilitate 
the endocytosis of each other, in the β2/κ opioid dimer the 
internalization of the β2AR was inhibited. Moreover, 
isoproterenol-induced MAPK activation was diminished in 
presence of κOR, showing that the κOR acts as a dominant 
negative modulator of the β2AR [81].  
 The same group explored the possible interaction 
between α2AR and opioid receptors that colocalize in 
neurons and affect the nociceptive response. The α2A/µ 
opioid could be isolated from recombinant cells as well as 
from primary neurons. In the α2A/µ opioid dimer the 
activation of each monomer increases G protein and MAPK 
signaling whereas the activation of both monomers decreases 
it [86]. In addition, when the receptors were expressed in a 
neuronal cell line the α2AAR increased the δOR-mediated 
neurite outgrowth [87]. These results support the notion that 
α2AR and opioid receptors are synergic in spinal analgesia 
as also demonstrated by the decrease in morphine-induced 
analgesia in α2A-/- knock out mice. Thus, the physical 
association between the α2AR and opioid receptors might 
explain their functional interaction.  
 Some interesting findings have been reported concerning 
the potential implications of βAR hetero-oligomerization 
with other GPCRs in native tissues. Whether in native tissues 
simultaneous synthesis of hetero-dimer partners can occur or 
different receptors are simply clustered in the same cell 
membrane compartment is not known. 
 In freshly isolated mouse cardiomyocytes, interesting 
effects were reported on contractility induced by angiotensin 
II (AgII) acting at AT1 receptor or isoproterenol acting at 
βAR [82]. Whereas the beta-blocker propranolol could 
inhibit the effect of AgII, the AT1 blocker valsartan inhibited 
that of isoproterenol. This transinhibitory effect of the two 
antagonists seemed related to inhibition of receptor coupling 
to its cognate G protein. Biochemical experiments on β2AR 
and AT1 receptor expressed in HEK cells indicated that the 
two receptors could be co-immunoprecipitated thus sug-
gesting that hetero-oligomerization of the two receptors 
could be the basis of their functional interaction in heart. 
 Hetero-oligomerization between the β2AR (coupled to 
Gs) and the EP1 prostaglandin receptor (coupled to Gq) has 
been observed in airway smooth muscle [84]. In mouse 
tracheal rings, activation of the β2AR induces muscle 
relaxation whereas stimulation of EP1 alone has no effect on 
contraction. However, stimulation of the EP1 receptor 
profoundly reduced the β2AR-induced muscle relaxation and 
cAMP accumulation. The modulatory effect of EP1 receptor 
on the β2AR might depend on the interaction between the 
two receptors which form heterodimers in airway smooth 
muscle cells. 
 Hetero-oligomerization has also been recently observed 
using BRET between the β2AR and the CB1 cannabinoid 
receptor expressed in recombinant cells [85]. The formation 
of oligomers could be increased by a CB1 inverse agonist. 
Interestingly, co-expression of the two receptors resulted in 
increased localization at the cell surface and decreased 
constitutive activity of the CB1 receptor. Complex functional 
interactions on signaling between the two receptors have 
been found both in the recombinant system and in primary 
human trabecular meshwork (HTM) cells from the eye, a 
tissue in which the two receptors are natively co-expressed. 
Beyond mutual effects on ERK activation, activation of one 
receptor induces cross-desensitization of the other both in 
recombinant and HTM cells. This might be relevant in drug 
therapy since CB1 agonists and β2AR antagonists can both 
reduce intraocular pressure.  
 Very recently, an elegant study demonstrated that the 
β2AR can form a signaling complex with the GluR1 subunit 
of the AMPA glutamate receptor including also the trimeric 
Gs protein, adenylate cyclase and protein kinase A [88]. This 
complex seems to be important to allow β2AR-induced 
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phosphorylation of the GluR1 which results in increased 
GluR1 cell surface expression and current amplitudes. 
CONCLUSIONS AND PERSPECTIVES 
 The AR subtypes have been found to interact with 
several proteins (Table 1) as well as to form homo and 
hetero-oligomers (Table 2). A critical approach in analyzing 
all these interactions should address a number of questions: 
is the interaction selective for one receptor or common to 
others? is it occurring in specific tissues? what are its 
functional implications? Addressing these questions is 
important to assess whether the interface of a receptor with a 
specific protein could be an interesting target of pharma-
cological intervention. For most interactions described at the 
Table 1. Proteins Selectively Interacting with Distinct Adrenergic Receptor Subtypes 
 
Receptor Partner Binding Site Functional Role Refs. 
β1 endophilins i3 loop (Pro-rich)  endocytosis [17] 
β1 PSD-95 C-tail (ESKV)  endocytosis; β1 /NMDA receptor association [18] 
β1 MAGI-2 C-tail (ESKV)  endocytosis; association to β-catenin [20] 
β1 GIPC C-tail (ESKV)  ERK activation [21] 
β1 CAL C-tail (ESKV)  cell surface expression [22] 
β1 CNrasGEF C-tail (ESKV) Ras activation [23] 
β1 MAGI-3 C-tail (ESKV)  ERK activation [25] 
β1 GASP C-tail (ESKV) unknown [26] 
β1 golgin-160 i3 loop  cell surface expression [28] 
β1 14-3-3 phospho-sites regulation of K+ current [29] 
β1 PDE4D8 unknown regulation of cAMP levels [30] 
β2 NHERF (or EBP50) C-tail (DSLL) regulation of NHE3; regulation of PDGF and CFTR activity; receptor recycling [31] 
β2 NSF C-tail (DSLL)  endocytosis [36] 
β2 AKAP250 (gravin) C-tail  endocytosis and resensitization;  association to GRK2 and βarrestin [38] 
β2 AKAP79 unknown  agonist-induced phosphorylation by GRK2 [40, 41] 
β2 Grb2 Tyr350/354  endocytosis stimulated by insulin [42] 
β2 Cav1.2 unknown  Ca++ current [44] 
β2 BKCa unknown  K+ current [45] 
β2 pVHL EGLN3 Pro382/395 O2-induced ubiquitinylation [46] 
β3 Src i3 loop and C-tail (Pro-rich)  ERK activation [13] 
α1a α1b α1d nNOS unknown unknown [47] 
α1a tolloid C-tail  surface expression [48] 
α1a RGS2 i3 loop (K219-S220-R238)  Gq signaling [49] 
α1b AP50 C-tail (8 Arg)  endocytosis [51] 
α1b ezrin C-tail (8 Arg)  recycling [52] 
α1b spinophilin i3 loop  Ca2+ signaling induced by RGS2 [61] 
α1d syntrophins C-term (ETDI) stabilization of receptor at cell surface [54] 
α1b α1d gC1qR C-tail (Arg) unknown [53] 
α2A α2B 
α2C 
14-3-3 z i3 loop unknown [55] 
α2A α2B 
α2C 
spinophilin i3 loop stabilization of receptor at cell surface;  arrestin action [55, 56] 
α2A Uch-L1 i3 loop  MAPK activation [62] 
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AR subtypes, the answers to these questions are far from 
being answered. 
 Most of the interactions involving the AR subtypes have 
been found using various screening approaches (proteomic, 
yeast two hybrid or pull-down experiments) without a 
specific bias towards the interactions searched. In most 
studies, the investigation of the interactions has been 
performed in recombinant systems in which only a limited 
number of functional parameters common to all GPCRs can 
be explored, i.e. trafficking, signaling through known path-
ways, receptor pharmacology. This resulted in the identifi-
cation of a number of proteins affecting receptor endocytosis 
(endophilins, PSD-95, MAGI-2, NSF, AKAP250, Grb2, 
AP50) and few others stabilizing receptor expression at the 
cell surface (golgin-160, spinophilin, syntrophin), favoring 
recycling (ezrin, NHERF) or regulating receptor coupling to 
G proteins (RGS2) (Table 1). Most of these interactions have 
been investigated only at a specific AR subtype with few 
exceptions. For example, the role of spinophilin in stabiliz-
ing receptor expression at the cell surface seems a property 
of all three α2AR subtypes (α2A, α2B and α2C) [55, 56]. 
Spinophilin has been found to interact also with the α1bAR 
displaying, however, a different effect, i.e. the modulation of 
calcium signaling. Spinophilin certainly represents a protein 
of pharmacological interest which should be further 
investigated because of its well established role in targeting 
the α2AR subtypes in polarized cells as well as in regulating 
their function.  
 It seems quite evident that proteins containing the PDZ 
domain can interact with both the β1 and β2AR. However, 
some PDZ domain containing proteins seem to display a 
selectivity towards either one of two receptors. For example, 
NHERF interacts with the C-tail of the β2AR, but not with 
the β1 [31]. PSD-95 interacts selectively with the β1AR being 
both proteins expressed in post-synaptic densities [18]. The 
interaction of PDZ proteins with the β1 and β2AR is also one 
of the few examples in which the functional implication has 
been investigated in a physiological system, i.e. mouse 
cardiac myocytes [24, 37]. Deletion of the PDZ binding 
motif in the β2AR abolished its coupling to Gi resulting in 
higher contraction rate, in contrast to the effect observed for 
the β1AR, where a similar mutation promoted Gi coupling 
and decreased contraction. Because of the functional rele-
vance of these interactions, PDZ domain containing proteins 
might represent interesting targets to pharmacologically 
interfere with trafficking and signaling of either the β1 or 
β2AR. Recently, some success has been reported in 
designing small peptides blocking PDZ interactions [89]. In 
addition, despite the wide distribution of PDZ proteins, the 
overlapping expression of interacting partners might be 
restricted to some tissues and this could be functionally 
relevant. More detailed studies on this important family of 
proteins in the regulation of AR subtypes are required and 
might have important implications. 
 Beyond the various interacting proteins found using 
different screening approaches, few highly interesting  
 
Table 2. Hetero-Oligomerization of the Adrenergic Receptors 
 
Receptors Trafficking Pharmacology Signaling Refs. 
β1/β2 no β2 endocytosis   β2 ERK activation [74] 
β2/β3 no β2 endocytosis  no Gi/o coupling [75] 
β2/Olf  Olf surface expression; co-endocytosis   [80] 
β2/δOR co-endocytosis   [81] 
β2/kOR no β2 endocytosis   β2 MAPK activation [81] 
β2/AT1 trans-inhibition of endocytosis by antagonists  
trans-inhibition of G protein coupling by 
antagonists [82] 
β2/5-HT4    [83] 
β2/EP1    β2 smooth muscle relaxation [84] 
β2/CB1  constitutive endocytosis of CB1; co-endocytosis  mutual effects on signaling; cross-desensitization [85] 
α1a/α1b co-endocytosis no change  [66] 
α1b/α1d  α1d surface expression  α1d affinity for selective ligands  signaling 
[67, 
76] 
α1d/β2  α1d surface expression; co-endocytosis   [77] 
α2A/α2c    α2A phosphorylation & βarrestin recruitment [68] 
α2A/β1 co-endocytosis altered β1 profile  [78] 
α2C/β2  α2C surface expression   α2C ERK signaling [79] 
α2A/µOR    signalling of each monomer [86] 
α2A/δOR    δOR neurite outgrowth [87] 
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interactions have been found in elegant studies exploring the 
activity of the β2AR in neuronal cells. The β2AR was found 
to directly interact with the voltage-gated calcium channel 
Cav1.2 in hippocampal neurons [44]. It was reported that the 
β2AR can also interact with calcium sensitive K+ channels 
(BKCa) in a complex containing the receptor, BKCa and 
AKAP79 [42]. Thus, the β2AR might interact with both the 
Cav1.2 calcium channel and the BKCa calcium sensitive K+ 
channel, and these interactions might enable a highly loca-
lized control of membrane excitability. Another recent study 
has reported that the β2AR can form a signaling complex 
with the GluR1 subunit of the AMPA glutamate receptor 
including also the trimeric Gs protein, adenylate cyclase and 
protein kinase A [88]. This complex might underlie the faci-
litating effect of βARs on long term potentiation mediated by 
AMPA receptors. 
 Altogether, these latter studies clearly indicate that the 
full elucidation of signaling events in time and space will 
depend on a much deeper understanding of the interactions 
among receptors and signaling molecules. Developing drugs 
acting at distinct receptor-protein interfaces might represent 
an approach to achieve more cell specific pharmacological 
effects. However, this field is still at an early stage because 
of the complexity of studying these events in physiological 
cell systems as demonstrated by the limited number of 
studies published so far. Therefore, the fine-tuning of GPCR 
activity by receptor-interacting proteins is a very promising 
area of investigation in which a lot remains to be explored 
[90]. Studies in recombinant systems can certainly provide 
some useful information, but the real challenge concerns the 
possibility of exploring the functional implications of a 
variety of interactions in different tissues and physiological 
conditions. Without these studies it will be difficult to assess 
which of these interactions are druggable. 
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